Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Garraway, 2013, Genomics-driven oncology: framework for an emerging paradigm, J Clin Oncol, 31, 1806, 10.1200/JCO.2012.46.8934

MacConaill, 2011, Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges, Cancer Discov, 1, 297, 10.1158/2159-8290.CD-11-0110

Taylor, 2011, Clinical cancer genomics: how soon is now?, J Pathol, 223, 318, 10.1002/path.2794

Romano, 2011, Treatment implications of the emerging molecular classification system for melanoma, Lancet Oncol, 12, 913, 10.1016/S1470-2045(10)70274-6

Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782

Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886

Shaw, 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 370, 1189, 10.1056/NEJMoa1311107

Kris, 2014, Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, 311, 1998, 10.1001/jama.2014.3741

Tsongalis, 2014, Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations, Clin Chem Lab Med, 52, 707, 10.1515/cclm-2013-0883

Luthra, 2014, Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring, Haematologica, 99, 465, 10.3324/haematol.2013.093765

Abel, 2014, Detection of gene rearrangements in targeted clinical next-generation sequencing, J Mol Diagn, 16, 405, 10.1016/j.jmoldx.2014.03.006

Cottrell, 2014, Validation of a next-generation sequencing assay for clinical molecular oncology, J Mol Diagn, 16, 89, 10.1016/j.jmoldx.2013.10.002

Pritchard, 2014, Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens, J Mol Diagn, 16, 56, 10.1016/j.jmoldx.2013.08.004

Singh, 2013, Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes, J Mol Diagn, 15, 607, 10.1016/j.jmoldx.2013.05.003

Duncavage, 2012, Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia, Mod Pathol, 25, 795, 10.1038/modpathol.2012.29

Kanagal-Shamanna, 2014, Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics, Mod Pathol, 27, 314, 10.1038/modpathol.2013.122

Frampton, 2013, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, 31, 1023, 10.1038/nbt.2696

Van Allen, 2014, Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nat Med, 20, 682, 10.1038/nm.3559

Lin, 2014, Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing, Am J Clin Pathol, 141, 856, 10.1309/AJCPMWGWGO34EGOD

Nikiforova, 2013, Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer, J Clin Endocrinol Metab, 98, E1852, 10.1210/jc.2013-2292

Cheng, 2014, Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data, J Mol Diagn, 16, 504, 10.1016/j.jmoldx.2014.05.006

Won, 2013, Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing, J Vis Exp, e50710

Huang, 2013, Highly recurrent TERT promoter mutations in human melanoma, Science, 339, 957, 10.1126/science.1229259

Landa, 2013, Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease, J Clin Endocrinol Metab, 98, E1562, 10.1210/jc.2013-2383

Killela, 2013, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal, Proc Natl Acad Sci U S A, 110, 6021, 10.1073/pnas.1303607110

Vinagre, 2013, Frequency of TERT promoter mutations in human cancers, Nat Commun, 4, 2185, 10.1038/ncomms3185

McKenna, 2010, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res, 20, 1297, 10.1101/gr.107524.110

Forbes, 2008, The Catalogue of Somatic Mutations in Cancer (COSMIC), Curr Protoc Hum Genet, 10.1002/0471142905.hg1011s57

Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat Biotechnol, 31, 213, 10.1038/nbt.2514

Wang, 2010, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data, Nucleic Acids Res, 38, e164, 10.1093/nar/gkq603

Horaitis, 2004, The challenge of documenting mutation across the genome: the human genome variation society approach, Hum Mutat, 23, 447, 10.1002/humu.20038

Kent, 2002, The human genome browser at UCSC, Genome Res, 12, 996, 10.1101/gr.229102

Abecasis, 2012, An integrated map of genetic variation from 1,092 human genomes, Nature, 491, 56, 10.1038/nature11632

Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095

Robinson, 2011, Integrative genomics viewer, Nat Biotechnol, 29, 24, 10.1038/nbt.1754

Olshen, 2004, Circular binary segmentation for the analysis of array-based DNA copy number data, Biostatistics, 5, 557, 10.1093/biostatistics/kxh008

Rausch, 2012, DELLY: structural variant discovery by integrated paired-end and split-read analysis, Bioinformatics, 28, i333, 10.1093/bioinformatics/bts378

Ye, 2009, Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads, Bioinformatics, 25, 2865, 10.1093/bioinformatics/btp394

Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer, Nat Biotechnol, 30, 413, 10.1038/nbt.2203

Roth, 2014, PyClone: statistical inference of clonal population structure in cancer, Nat Methods, 11, 396, 10.1038/nmeth.2883